Please login to the form below

Not currently logged in


This page shows the latest Janssen news and features for those working in and with pharma, biotech and healthcare.

FDA clears first-line use for J&J’s myeloma drug Darzalex

FDA clears first-line use for J&J’s myeloma drug Darzalex

Frontline approval for Janssen's Darzalex a milestone in march towards blockbuster status. ... The company’s Janssen unit says Darzalex (daratumumab) has been given the nod for use alongside Takeda’s Velcade (bortezomib), melphalan and prednisone (VMP

Latest news

More from news
Approximately 123 fully matching, plus 341 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Product / Technology. Deal Type. Headline. ($). Arrowhead/. Janssen (J&J). Development &commercialisation of ARO‐HBV, based on.

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    The firm also has what it hopes is a best- in-class BTK inhibitor, zanubrutinib, in phase III trials, which it believes can be shown superior to Janssen’s Imbruvica.

  • The race for a HIV ‘cure’ The race for a HIV ‘cure’

    Gilead’s HIV work continues apace as does that of rivals GSK, Sanofi, Janssen and others in a global HIV drug market expected to reach a value of $26, 458bn in

  • A quest for innovative solutions A quest for innovative solutions

    Janssen adds: “We spend a lot of time asking how we, as an organisation, can prepare for this future because it is happening right now. ... There are some really exciting projects out there and we are also partnering with academic institutions to use

  • Pharma deals continue to slide Pharma deals continue to slide

    These companies have been running out of cash and have had to do deals to stay alive.  Cerecor has sold its kappa opioid receptor antagonist in phase 2 to Janssen ... 74.5 (upfront 65). Cerecor (US). J&J/Janssen (US). Asset acquisition. CERC-501 phase

More from intelligence
Approximately 5 fully matching, plus 45 partially matching documents found.

Latest appointments

More from appointments
Approximately 3 fully matching, plus 24 partially matching documents found.

Latest from PMHub

  • Attigo (part of the Mednet Group)

    Clinigen. Crohns and Colitis Department for International Development. Eisai. Gilead. Janssen.

  • Janssen & Research Partnership win prestigious BHBIA Best Business Impact award

    We are delighted to announce that Janssen and Research Partnership have won the BOBI (Best of Business Intelligence) Award in the Best Business Impact category at the BHBIA annual conference in

  • Adelphi Research UK wins Agency of the Year at BHBIA Conference

    Adelphi, Janssen and Rethink Mental Illness pro-bono work wins BHBIA Best Conference Paper. ... Adelphi were already excited to work with Janssen and Rethink to generate findings around the Mental Health Act to help lobby government changes, but to have

  • No Voice, No Choice

    The research was commissioned by Rethink Mental Illness and undertaken by Adelphi Research UK, with support from Janssen Cilag Ltd. ... Rachel Medcalf, Managing Director, Adelphi Research UK commented:. “It’s great to be involved in this crucial

  • Synergy Vision

    Amgen. Daiichi Sankyo. GlaxoSmithKline. Janssen Cilag. LEO Pharma. The Menarini Group.

More from PMHub
Approximately 5 fully matching, plus 28 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...